Harbor Investment Advisory LLC Sells 1,374 Shares of Zoetis Inc. (NYSE:ZTS)

Harbor Investment Advisory LLC trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 17.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,547 shares of the company’s stock after selling 1,374 shares during the quarter. Harbor Investment Advisory LLC’s holdings in Zoetis were worth $1,067,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Darwin Wealth Management LLC purchased a new position in Zoetis in the third quarter worth about $31,000. First Personal Financial Services bought a new position in shares of Zoetis in the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis during the third quarter valued at approximately $33,000. Dunhill Financial LLC increased its holdings in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the last quarter. Finally, Quarry LP raised its position in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Up 1.0 %

Zoetis stock opened at $167.50 on Wednesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The firm’s 50 day moving average price is $170.73 and its 200-day moving average price is $179.95. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The stock has a market cap of $75.57 billion, a P/E ratio of 31.49, a PEG ratio of 2.55 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.36 EPS. On average, equities analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.19%. The ex-dividend date of this dividend is Tuesday, January 21st. This is a boost from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio (DPR) is currently 37.59%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ZTS shares. Stifel Nicolaus cut their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. JPMorgan Chase & Co. upped their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. UBS Group started coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.